In Vivo CRO Market Analysis

In Vivo CRO Market Analysis

The market based on animal model is segmented into rodent-based and non-rodent-based animal models. The rodent-based segment is further segmented into rat models, mice models, and other rodent models. The rodent-based segment dominated the market in 2023 with a revenue of USD 3.8 billion.
 

• Rodents, especially mice and rats, are the most used animals in preclinical research due to their genetic, physiological, and anatomical similarities to humans. They are relatively easy to handle, breed quickly, and are cost-effective, making them ideal for large-scale studies.
   
• Additionally, their small size allows for housing in large numbers, facilitating statistical analysis and reducing variability.
   
• Moreover, the availability of well-characterized strains and genetically modified models further enhances their utility in studying various diseases and conditions.
   

The in vivo CRO market based on service is classified into bioanalysis & DMPK studies, toxicity studies, biocompatibility testing, microbiological testing, and other services. The bioanalysis & DMPK studies segment dominated the market in 2023 with a market share of 40.6%.
 

• Bioanalysis & DMPK studies are crucial in drug development, providing critical information on how a drug is metabolized and distributed in the body, its pharmacological activity, and its potential toxicity. As regulatory agencies increasingly demand comprehensive data on these aspects, the need for bioanalysis & DMPK studies has grown significantly.
   
• Additionally, the complexity of new drug candidates, including biologics and gene therapies, further drives the demand for these services.
   

Based on drug type, the in vivo CRO market is classified into small molecule drugs and large molecule drugs. The small molecule drugs segment dominated the market and is expected to exhibit 7.9% CAGR between 2024 - 2032.
 

• Small molecule drugs offer advantages such as oral bioavailability, which enhances patient compliance, and well-established formulation techniques, leading to easier manufacturing processes.
   
• Additionally, these drugs often have a broader range of target diseases compared to biologics, making them attractive for pharmaceutical companies seeking to address a variety of medical conditions.
   
• Moreover, the robust pipeline of small molecule drugs in development further drives the demand for in vivo CRO services, as companies rely on these organizations for preclinical and clinical studies to assess the safety and efficacy of their compounds.
   

The in vivo CRO market based on therapeutic area is segmented into oncology, clinical pharmacology, cardiology, infectious diseases, neurology, gastroenterology & hepatology, metabolic & endocrine, ophthalmology, autoimmune / inflammatory conditions, and other therapeutic areas. The oncology segment is expected to reach USD 5.2 billion by 2032.
 

• The increasing incidence of cancer worldwide has led to a surge in research and development activities focused on oncology treatments. This has created a significant demand for in vivo CRO services specializing in oncology studies.
   
• Additionally, the complexity of oncology drug development, which often requires a combination of preclinical and clinical studies, drives pharmaceutical and biotechnology companies to outsource these tasks to specialized CROs.
   
• The oncology segment's high market share is further bolstered by the rising investments in oncology research, favorable government initiatives, and the growing trend of personalized medicine in cancer treatment, all of which contribute to the segment's strong growth trajectory within the market.
   

The in vivo CRO market based on end-use is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic & research institutes. The pharmaceutical & biopharmaceutical companies’ segment dominated the market in 2032 and is anticipated to grow at a CAGR of 8% over the forecast years.
 

• Pharmaceutical & biopharmaceutical companies rely heavily on CROs to conduct preclinical trials in animal models for their drug candidates, as outsourcing these services streamlines the drug development process and reduce costs.
   
• Furthermore, the increasing complexity of drug development, including the need for specialized expertise, genetically modified animal models, and technologies, has led these companies to seek partnerships with specialized CROs that provide in-vivo services.
   
• As a result, pharmaceutical and biopharmaceutical companies play a crucial role in driving the growth of market.
   

North America in vivo CRO market accounted for USD 2 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.6% between 2024 – 2032.
 

• The region's well-established pharmaceutical and biotechnology industries, coupled with a robust healthcare infrastructure and favorable regulatory environment, contribute to its dominance.
   
• Additionally, the presence of major market players and a strong emphasis on drug discovery and development, supported by significant investments in R&D by pharmaceutical and biotechnology companies further bolster the market.
   
• Moreover, the presence of a large patient population, particularly for chronic and lifestyle-related diseases, creates a robust demand for clinical trials and research services, thereby propelling the regional market growth.